Nectar Group's HoneyB, a Bitcoin yield platform targeting institutions, has raised $5 million in a seed round, valuing the startup at $30 million. HoneyB aims to help institutional Bitcoin holders earn yield by using BTC as collateral to borrow stablecoins, which are then invested in tokenized real-world asset strategies expected to generate around 12% gross annual returns. The platform avoids common risks by not requiring BTC wrapping or bridging and uses tri-party custody for security and compliance. Currently in pre-launch, HoneyB has no live product or metrics yet; key upcoming milestones include its official launch, total value locked, and actual net yields delivered to users.
Nectar Group's HoneyB Bitcoin yield platform is the subject, with Pluang market data provided as context. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 21, 2026 00:22 WIB: out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell. Notable movers include ALGO at Rp2.039 with a 3.82% increase, MANA at Rp1.560 up 3.65%, and SUSHI at Rp4.028 rising 3.61%.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
